Habitrol labeling changes
This article was originally published in The Tan Sheet
Executive Summary
FDA approves supplemental NDA 20-076/S-021 for labeling changes to Novartis' Habitrol smoking cessation patch on July 15. New packaging will incorporate current pregnancy/breastfeeding warning, as requested by FDA in 2001 (1"The Tan Sheet" August 27, 2001, p. 3). Changes will appear on "Drug Facts" box of 7 mg, 14 mg and 21 mg Habitrol cartons. Revised labeling also will be reflected on multi-dose Habitrol kit, which was approved as the first 3-in-1 smoking cessation offering in July (2"The Tan Sheet" July 22, 2002, p. 4)...
You may also be interested in...
Novartis Habitrol Approval Marks First 3-In-1 Smoking Cessation Kit
Novartis Consumer Healthcare's Habitrol multi-dose smoking cessation kit will represent the first time an entire course of nicotine replacement therapy is available in a single package
Smoking Cessation Pregnancy Data Required For Alternative Warning Use
OTC nicotine-replacement therapy manufacturers who wish to use a pregnancy/breastfeeding warning different from new, FDA-revised labeling "will have to provide data to support alternative wording," the agency says.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.